A lot of patients have received complete response (CR) or partial response (PR) under the PI3K/Akt/mTOR inhibitors treatment, providing important indications and possibilities for ESCC therapy (Supplementary Table S2). The gene discussed is PIK3CA; the disease is esophageal squamous cell carcinoma.